Attovia Therapeutics (NASDAQ:ATTO) Posts Earnings Results, Misses Expectations By $0.02 EPS

Attovia Therapeutics (NASDAQ:ATTO) posted its earnings results on Monday. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02), Zacks reports. The company’s revenue was down 100.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($3.44) earnings per share.

Attovia Therapeutics Stock Up 3.8%

Shares of NASDAQ:ATTO traded up $0.63 during midday trading on Wednesday, hitting $17.27. The stock had a trading volume of 9,379 shares, compared to its average volume of 343,183. The stock has a 50-day moving average price of $17.97. The company has a market capitalization of $788.30 million and a P/E ratio of -3.54. Attovia Therapeutics has a fifty-two week low of $12.94 and a fifty-two week high of $28.00.

Wall Street Analyst Weigh In

ATTO has been the subject of several recent research reports. Leerink Partners started coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an “outperform” rating and a $52.00 price target for the company. Wall Street Zen upgraded Attovia Therapeutics to a “sell” rating in a research report on Saturday, September 19th. Citigroup increased their price objective on Attovia Therapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Tuesday. Zacks Research raised Attovia Therapeutics to a “hold” rating in a report on Friday, September 4th. Finally, Morgan Stanley boosted their target price on shares of Attovia Therapeutics from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.20.

Attovia Therapeutics Company Profile

Attovia Therapeutics is a clinical-stage biotechnology company developing medicines for inflammatory and immune-mediated diseases. Its research focuses on antibody-based therapies intended to address biological pathways involved in these conditions. The company’s programs are in development, and its work centers on discovering and advancing potential treatments rather than marketing established products. Attovia Therapeutics is listed on the Nasdaq under the symbol ATTO. Publicly available information about the company’s history, leadership and geographic operations is limited.